U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07221292) titled 'Pivotal Study of N-acetyl-L-leucine for CACNA1A' on Oct. 24.
Brief Summary: A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of CACNA1A. The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.
Study Start Date: Sept. 01, 2026
Study Type: INTERVENTIONAL
Condition:
CACNA1A
Spinocerebellar Ataxia Type 6
Episodic Ataxia Type 2
Familial Hemiplegic Migraine-1
Intervention:
DRUG: N-Acetyl-L-Leucine
N-Acetyl-L-Leucine is a modified amino-acid ester that is...